Biosimilar Switch

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the therapeutic management of inflammatory rheumatic diseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.

  • Reasons of Switching
  • Immunogenicity
  • Switching of bDMARD to its Biosimilars
  • Switches in Clinical Trails